- Home
- JSPR vs MRSN Comparison
JSPR vs MRSN Comparison
Compare JSPR & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JSPR
- MRSN
- Stock Information
- Founded
- JSPR 2018
- MRSN 2001
- Country
- JSPR United States
- MRSN United States
- Employees
- JSPR N/A
- MRSN N/A
- Industry
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- JSPR Health Care
- MRSN Health Care
- Exchange
- JSPR Nasdaq
- MRSN Nasdaq
- Market Cap
- JSPR 85.8M
- MRSN 40.7M
- IPO Year
- JSPR N/A
- MRSN 2017
- Fundamental
- Price
- JSPR $4.43
- MRSN $0.34
- Analyst Decision
- JSPR Strong Buy
- MRSN Buy
- Analyst Count
- JSPR 10
- MRSN 3
- Target Price
- JSPR $62.50
- MRSN $4.00
- AVG Volume (30 Days)
- JSPR 155.4K
- MRSN 2.3M
- Earning Date
- JSPR 05-20-2025
- MRSN 05-15-2025
- Dividend Yield
- JSPR N/A
- MRSN N/A
- EPS Growth
- JSPR N/A
- MRSN N/A
- EPS
- JSPR N/A
- MRSN N/A
- Revenue
- JSPR N/A
- MRSN $40,497,000.00
- Revenue This Year
- JSPR N/A
- MRSN N/A
- Revenue Next Year
- JSPR N/A
- MRSN N/A
- P/E Ratio
- JSPR N/A
- MRSN N/A
- Revenue Growth
- JSPR N/A
- MRSN 9.88
- 52 Week Low
- JSPR $3.13
- MRSN $0.26
- 52 Week High
- JSPR $26.84
- MRSN $3.50
- Technical
- Relative Strength Index (RSI)
- JSPR 44.42
- MRSN 44.05
- Support Level
- JSPR $4.27
- MRSN $0.35
- Resistance Level
- JSPR $5.67
- MRSN $0.44
- Average True Range (ATR)
- JSPR 0.44
- MRSN 0.04
- MACD
- JSPR 0.01
- MRSN 0.00
- Stochastic Oscillator
- JSPR 28.32
- MRSN 18.32
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.